VECT Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 jul 2023 @ 21:59):

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions...

Stats
Dagens volum	127 653
Gjennomsnittsvolum	1.10M
Markedsverdi	1.06B
EPS	$0 ( 2023-07-19 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.03
ATR14	$0.430 (2.55%)

Volum Korrelasjon

Lang: 0.33 (neutral)

Kort: -0.50 (neutral)

Signal:(67.1) Neutral

VectivBio Holding AG Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

VectivBio Holding AG Korrelasjon - Valuta/Råvare

0.29
( neutral )

0.56
( weak )

-0.32
( neutral )

-0.23
( neutral )

0.47
( neutral )

0.68
( moderate )

VectivBio Holding AG Økonomi

Annual	2022
Omsetning:	$27.34M
Bruttogevinst:	$27.34M (100.00 %)
EPS:	$-2.12

FY	2022
Omsetning:	$27.34M
Bruttogevinst:	$27.34M (100.00 %)
EPS:	$-2.12

Financial Reports:

No articles found.

VectivBio Holding AG

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.